-
Something wrong with this record ?
A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment
M Hroch, J Chladek, M Simkova, J Vaneckova, J Grim, J Martinkova
Language English Country Great Britain
Document type Clinical Trial
Grant support
NR7947
MZ0
CEP Register
Digital library NLK
Full text - Část
Source
NLK
Wiley Online Library (archiv)
from 1997-01-01 to 2012-12-31
- MeSH
- Administration, Oral MeSH
- Dermatologic Agents administration & dosage pharmacokinetics blood MeSH
- Adult MeSH
- Erythrocytes metabolism MeSH
- Financing, Organized MeSH
- Middle Aged MeSH
- Humans MeSH
- Methotrexate administration & dosage pharmacokinetics blood MeSH
- Drug-Related Side Effects and Adverse Reactions MeSH
- Pilot Projects MeSH
- Psoriasis drug therapy blood MeSH
- Drug Administration Schedule MeSH
- Aged MeSH
- Severity of Illness Index MeSH
- Treatment Outcome MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Clinical Trial MeSH
BACKGROUND: Clinical studies of low-dose oral methotrexate (MTX) in the treatment of psoriasis and rheumatoid arthritis document a large interpatient variability in the pharmacokinetics of MTX, including its polyglutamates (MTXPGs) in erythrocytes (RBC). This can be a factor contributing to the variability of therapeutic and toxic effects. AIM: This pilot trial aimed to investigate the MTXPG concentrations in RBC as well as their relation to therapeutic and adverse effects during the initial 4 months of pharmacokinetically guided therapy with a divided-dose schedule (three doses of MTX separated by 12-h intervals once a week). SUBJECTS AND METHODS: Sixteen psoriatic patients (4 men and 12 women; mean age, 53 years; range, 28-69 years) with moderate-to-severe chronic plaque psoriasis [mean Psoriasis Area and Severity Index (PASI) = 24; range, 9-42] were enrolled in the study. Concentrations of plasma MTX and that of MTXPGs in RBC were assayed using liquid chromatography methods. The area under the concentration-time curve of plasma MTX in the interval 0-8 h post-dose (AUC(0-8 h)) was measured after a test bolus dose of 10 mg, and the starting weekly dose was individualized in order to achieve the target AUC(0-8 h) of 1800 nmol.h/L. The PASI, biochemistry, and haematology tests and MTXPGs levels in RBC were evaluated at baseline and at 4-week intervals. RESULTS: The AUC(0-8 h )achieved 1360 +/- 425 nmol.h/L (mean +/- SD: range, 778-2400 nmol.h/L). The mean (range) of individualized doses was 14.5 mg/week (7.5-22.5 mg). The mean (SD) steady-state concentration of total MTXPGs observed between days 85 to 110 reached 113 (34.6) nmol/L (range, 66.1-174 nmol/L). The PASI decreased from 24.0 +/- 8.0 (mean +/- SD) at baseline to 8.0 +/- 6.1 at day 110 (P < 0.001). Thirteen patients (87%) achieved a greater than 50% improvement in baseline PASI, and seven (47%) experienced a greater than 75% improvement. There was no relationship between the percent improvement from baseline PASI and the steady-state concentration of MTXPGs in RBC. All patients tolerated MTX well. Throughout the study period, there was a continuous increasing trend in the geometric mean values of the mean corpuscular volume from 92.6 to 96.4 fL (P < 0.001) and of plasma homocysteine from 9.5 to 12.3 micromol/L (P < 0.005). The geometric mean serum alanine aminotransferase (ALT) activity slightly increased from 0.49 to 0.80 microkat/L (P < 0.05). However, only two patients had the ALT activity transiently elevated above twice the upper limit of normal. CONCLUSION: Results of this pilot trial show that the steady-state levels of MTXPGs in RBC vary less than threefold between patients and did not correlate with the change in PASI observed after 4 months of therapy with an individualised weekly dose of MTX. Whether pharmacokinetically guided dosing can improve the results of psoriasis therapy with MTX should be prospectively tested in large controlled studies.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10026317
- 003
- CZ-PrNML
- 005
- 20130917102438.0
- 008
- 101018s2008 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Hroch, Miloš, $d 1976- $7 xx0076212
- 245 12
- $a A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment / $c M Hroch, J Chladek, M Simkova, J Vaneckova, J Grim, J Martinkova
- 314 __
- $a Department of Pharmacology, Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic.
- 520 9_
- $a BACKGROUND: Clinical studies of low-dose oral methotrexate (MTX) in the treatment of psoriasis and rheumatoid arthritis document a large interpatient variability in the pharmacokinetics of MTX, including its polyglutamates (MTXPGs) in erythrocytes (RBC). This can be a factor contributing to the variability of therapeutic and toxic effects. AIM: This pilot trial aimed to investigate the MTXPG concentrations in RBC as well as their relation to therapeutic and adverse effects during the initial 4 months of pharmacokinetically guided therapy with a divided-dose schedule (three doses of MTX separated by 12-h intervals once a week). SUBJECTS AND METHODS: Sixteen psoriatic patients (4 men and 12 women; mean age, 53 years; range, 28-69 years) with moderate-to-severe chronic plaque psoriasis [mean Psoriasis Area and Severity Index (PASI) = 24; range, 9-42] were enrolled in the study. Concentrations of plasma MTX and that of MTXPGs in RBC were assayed using liquid chromatography methods. The area under the concentration-time curve of plasma MTX in the interval 0-8 h post-dose (AUC(0-8 h)) was measured after a test bolus dose of 10 mg, and the starting weekly dose was individualized in order to achieve the target AUC(0-8 h) of 1800 nmol.h/L. The PASI, biochemistry, and haematology tests and MTXPGs levels in RBC were evaluated at baseline and at 4-week intervals. RESULTS: The AUC(0-8 h )achieved 1360 +/- 425 nmol.h/L (mean +/- SD: range, 778-2400 nmol.h/L). The mean (range) of individualized doses was 14.5 mg/week (7.5-22.5 mg). The mean (SD) steady-state concentration of total MTXPGs observed between days 85 to 110 reached 113 (34.6) nmol/L (range, 66.1-174 nmol/L). The PASI decreased from 24.0 +/- 8.0 (mean +/- SD) at baseline to 8.0 +/- 6.1 at day 110 (P < 0.001). Thirteen patients (87%) achieved a greater than 50% improvement in baseline PASI, and seven (47%) experienced a greater than 75% improvement. There was no relationship between the percent improvement from baseline PASI and the steady-state concentration of MTXPGs in RBC. All patients tolerated MTX well. Throughout the study period, there was a continuous increasing trend in the geometric mean values of the mean corpuscular volume from 92.6 to 96.4 fL (P < 0.001) and of plasma homocysteine from 9.5 to 12.3 micromol/L (P < 0.005). The geometric mean serum alanine aminotransferase (ALT) activity slightly increased from 0.49 to 0.80 microkat/L (P < 0.05). However, only two patients had the ALT activity transiently elevated above twice the upper limit of normal. CONCLUSION: Results of this pilot trial show that the steady-state levels of MTXPGs in RBC vary less than threefold between patients and did not correlate with the change in PASI observed after 4 months of therapy with an individualised weekly dose of MTX. Whether pharmacokinetically guided dosing can improve the results of psoriasis therapy with MTX should be prospectively tested in large controlled studies.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a dermatologické látky $x aplikace a dávkování $x farmakokinetika $x krev $7 D003879
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a nežádoucí účinky léčiv $7 D064420
- 650 _2
- $a erytrocyty $x metabolismus $7 D004912
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a methotrexát $x aplikace a dávkování $x farmakokinetika $x krev $7 D008727
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a psoriáza $x farmakoterapie $x krev $7 D011565
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a financování organizované $7 D005381
- 655 _2
- $a klinické zkoušky $7 D016430
- 700 1_
- $a Chládek, Jaroslav, $d 1962- $7 xx0057856
- 700 1_
- $a Šimková, Marie $7 xx0153126
- 700 1_
- $a Vaněčková, Jaroslava, $d 1945- $7 jn20020220009
- 700 1_
- $a Grim, Jiří $7 xx0143078
- 700 1_
- $a Martínková, Jiřina, $d 1940- $7 nlk19990073537
- 773 0_
- $w MED00002983 $t Journal of the European Academy of Dermatology and Venereology $g Roč. 22, č. 1 (2008), s. 19-24 $x 0926-9959
- 910 __
- $a ABA008 $b x $y 7
- 990 __
- $a 20101116104621 $b ABA008
- 991 __
- $a 20130917102943 $b ABA008
- 999 __
- $a ok $b bmc $g 801422 $s 666168
- BAS __
- $a 3
- BMC __
- $a 2008 $b 22 $c 1 $d 19-24 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venerol $x MED00002983
- GRA __
- $a NR7947 $p MZ0
- LZP __
- $a 2010-B/jtme